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Background: Thyroid nodules are routinely evaluated with ultrasound. Our aim was to determine if thyroid
nodule location was a useful feature to predict thyroid cancer.
Materials and Methods: Retrospective review of patients with thyroid nodules from six referral centers from
2006 to 2010. A total of 3313 adult patients with thyroid nodules and confirmed benign or malignant thyroid
diagnoses were included.
Results: Mean patient age was 54.2 (18–97) years, and the majority were women (n = 2635, 79.8%). A total of
3241 nodules were analyzed, 335 (10.3%) of which were malignant. Thyroid nodule location was an inde-
pendent risk factor in predicting thyroid cancer ( p = 0.005). Thyroid cancer odds were highest in the isthmus
(odds ratio [OR] = 2.4, 95% confidence interval [CI] 1.6–3.6, p < 0.0001). In a multivariate regression model
adjusting for age, sex, family history of thyroid cancer, radiation exposure, nodule size, and American College
of Radiology (ACR) TI-RADS (Thyroid Imaging Reporting and Data System) score, the isthmus nodules had
the highest risk of malignancy (OR = 2.4 [CI 1.5–3.9], p = 0.0007), followed by upper thyroid nodules (OR = 1.8
[CI 1.2–2.7], p = 0.005) and then middle thyroid nodules (OR = 1.5 [CI 1.1–2.0], p = 0.01) compared with lower
thyroid nodules. Isthmus nodules were significantly smaller in size compared with middle ( p < 0.0001) and
lower ( p = 0.0004), but not upper nodules ( p = 0.25), with a mean size of 15.5 mm (–10.7).
Conclusions: Thyroid nodule location is an independent risk factor in predicting the risk of thyroid cancer.
Isthmic nodules carry the highest risk of cancer diagnosis and lower lobe nodules carry the lowest risk.
Keywords: thyroid nodule, ACR TI-RADS, location, isthmus, thyroid cancer
Introduction
Thyroid nodules are common in clinical practice. Theestimated prevalence of thyroid nodules detected using
high-resolution ultrasound (US) can range from 19% to 68%
with higher frequencies in older adults and women (1,2).
Thyroid nodule evaluation is particularly important to
exclude thyroid cancer. Thyroid US is used to identify nod-
ules for fine-needle aspiration (FNA) sampling. Cytological
analysis of FNA samples is the safest and most cost-effective
diagnostic tool available for the clinical evaluation of ma-
lignancy in thyroid nodules (3,4); However, it is an invasive
procedure and may carry its own complication risks (5).
The incidence of thyroid nodules is dramatically increas-
ing, in part, due to incidental detection of nodules on imaging
studies for other indications. The reported thyroid malig-
nancy prevalence can range from 7% to 15% (6), which
means the majority of all biopsied thyroid nodules are non-
malignant. However, since the early 1990s, the thyroid can-
cer incidence has been increasing more than any other cancer
type in the United States. In South Korea, screening for
thyroid cancer led to a 15-fold increase in the rate of thyroid
cancer diagnosis between 1993 and 2011 without a corre-
sponding increase in mortality (7). This is consistent with
overdiagnosis. While the dominant cause of the current
‘‘epidemic’’ of thyroid cancer is overdiagnosis, data from the
Surveillance, Epidemiology, and End Results -9 cancer reg-
istry program showed that trends in thyroid cancer incidence
from 1994 to 2013 were associated with an average relative
annual increase in mortality of 1.1% per year, suggesting that
a component of the epidemic is due to a small but real in-
crease in papillary thyroid cancer incidence (8). Moreover,
our understanding of the genetic mechanisms of thyroid
carcinogenesis has dramatically evolved over the last 2 de-
cades, leading to the clinical utility of molecular testing and
the impact on the clinical management of patients with thy-
roid nodules (9).
In addition to the considerable patient anxiety that can
occur because of the increasing incidence of thyroid nod-
ules, the cost of thyroid cancer care in the United States is
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estimated to reach $18–$21 billion in 2019 based on historic
incidence trends (10). This significant burden placed on pa-
tients and health care resources can be reduced by decreasing
unnecessary FNAs and surgical resection of nonmalignant
thyroid nodules.
Numerous guidelines have been developed within the last
decade to assist physicians in deciding when it is appropriate
to perform FNA versus observation of thyroid nodules in
low-risk adult patients. A risk-stratifying approach is cur-
rently used by the American Thyroid Association (ATA) and
American Association of Clinical Endocrinologist (AACE)
to determine if FNA sampling should be pursued (6,11).
The American College of Radiology (ACR) developed a
Thyroid Imaging Reporting and Data System (TI-RADS)
(12), which uses a point-based classification system for risk
stratification of thyroid nodules based on US features similar
to those used in the ATA guidelines. Points are added to
create an ACR TI-RADS scoring category (TR) ranging from
TR1 (0 points) or least suspicious nodule with no indication
for FNA or follow-up, to TR5 (‡7 points) being highly sus-
picious and requiring follow-up US if between 0.5 and 0.9 cm
and FNA if ‡1.0 cm.
Recently, two small studies proposed integrating nodule
location within the thyroid gland to risk stratification systems
(13,14). However, the inconsistent results and small sample
size of those studies called for validation in a larger study.
The aim of our study was to test the risk of thyroid malig-
nancy based on thyroid nodule location in a large multi-
institutional cohort of patients with biopsy-proven nodules.
Materials and Methods
This is a retrospective data analysis of an existing thyroid
nodule registry. The same database was previously used to
evaluate the ACR TI-RADS, and full details of the study
methods and original data collection are described in that
prior report (15). Approval for this analysis was granted by
the Washington University School of Medicine Institutional
Review Board.
Patients/subjects
Adult patients, 18 years or older, from six tertiary aca-
demic institutions in the United States who underwent thy-
roid nodule FNA between 2006 and 2010 were analyzed.
A total of 3313 patients with 3419 thyroid nodules were in-
cluded in the database. At the time of their FNA, patients
filled out a questionnaire that included information about
race/ethnicity, family history of thyroid cancer, and radiation
exposure. Patients with multiple thyroid nodules were ap-
proached similar to those with one nodule.
In patients who had more than one thyroid nodule, the
decision to biopsy those nodules was similar to that in case of
solitary nodules and was based primarily on the sonographic
appearance of the nodule.
Image analysis
Analysis of sonographic images of all biopsied nodules
was performed by two radiologists who were blinded to the
pathologic results. Nodules were assessed for composition,
echogenicity, margins, echogenic foci, size, location, and
multiplicity. The presence of suspicious lymph nodes was
also determined. For the purpose of this study, we analyzed
the relationship of thyroid nodule location with the risk of
thyroid cancer. Thyroid nodule location was categorized as
isthmus, upper lobe, middle lobe, and lower lobe. The thyroid
was subjectively divided into thirds to differentiate the upper,
middle, and lower lobes. Thyroid nodules occupying both the
middle and lower thyroid lobe were included in the lower
thyroid nodule category. Thyroid nodules occupying the
entire thyroid lobe were excluded from the analysis.
Pathology analysis
Cytology reports from the patients FNA and, when appli-
cable, surgical pathology reports of resected specimens were
collected from the six participating sites. Nodules with FNA
results that were interpreted as malignant (Bethesda 6) or
benign (Bethesda 2) were considered diagnostic and were
included in the final analysis. Almost all malignant nodules
were surgically removed, while most benign nodules were
not.
Nodules with nondiagnostic (Bethesda 1) or indeterminate
(Bethesda 3 and 4) FNA results were excluded unless sub-
sequent definitive FNA results were available or the nodule
was resected and histologic results were available. Nodules
with suspicious FNA results (Bethesda category 5) were also
excluded unless there was a subsequent definitive FNA or
surgery to confirm the diagnosis. As such, there were 66
Bethesda category 5 lesions that were included in the final
analysis. Forty of the included nodules were malignant and
26 were benign, which is compatible with the estimated risk
of malignancy of 60–75% for category 5 in the Bethesda
classification (16).
Statistical methods
We used descriptive statistics to summarize patient de-
mographics and the general characteristics of biopsied thy-
roid nodules. Data are presented as frequencies (percentages)
for categorical variables with means (standard deviations) or
(range) as appropriate for continuous variables.
Differences between categorical variables were assessed
using the chi-square test or Fisher exact test and between
continuous variables using Student’s t-test (parametric) or
Wilcoxon/Kruskal–Wallis test (nonparametric) as appropri-
ate. A p value <0.05 was considered statistically significant.
In Table 2, summarizing the thyroid nodule characteris-
tics, we used a two-sample t-test for maximum nodule size
to obtain the p-value. For all the other characteristics that
involved frequencies, we used a chi-square test and the
generated p-values were used for a simple two-group com-
parison.
Univariate and multivariate logistic regression analyses
were performed to estimate the odds ratios (ORs) of malig-
nancy and their 95% confidence intervals (95% CIs). p = 0.05
was considered statistically significant. We used contingency
table chi-square tests and multivariate binary logistic regres-
sion to test the association of thyroid nodule location with the
risk of thyroid cancer diagnosis. We adjusted for certain
variables that may influence the risk of thyroid cancer such as
patient age, sex, family history of thyroid cancer, radiological
features of thyroid nodule (shape, composition, echogenicity,
margin, and calcification), and scoring system. We also ad-
justed for the existing ACR TI-RADS score/category.















































For all univariate (unadjusted) and multivariate (adjusted)
models, thyroid nodule location differences were evaluated
with the log OR of each location pair and corrected for false
positivity with the Bonferroni adjustment. Statistical soft-
ware (SAS, version 9.4, SAS Institute) was used to conduct
data analyses.
Results
The mean patient age was 54.2 (range: 18–97) years. The
majority of patients were women (n = 2635, 79.8%) and
Caucasians (n = 2596, 80.7%). There was a self-reported
family history of thyroid cancer in 302 (9%), and radiation
exposure to the head and neck region in 435 (13%). Eight
hundred thirty-eight patients (25.8%) had a single nodule, the
remainder had two or more nodules (Table 1).
One hundred seventy-eight nodules were excluded from
the final analysis because data regarding nodule location
were missing (n = 117) or the nodule occupied the entire lobe
of the thyroid (n = 61). This left a total of 3241 nodules that
were ultimately analyzed. Three hundred thirty-five of these
nodules were malignant and 2906 were benign (Fig. 1).
Of the 335 cytologically proven malignant nodules in the
database, a total of 289 were resected and histology was
obtained. One hundred seventy-seven (52.8%) were papillary
cancer, 82 (24.5%) were a follicular variant of papillary
cancer, 15 (4.5%) were follicular cancer, 5 (1.5%) were
medullary cancer, 1 (0.3%) was anaplastic cancer, and 9
(2.7%) were other types of malignancies (Table 2).
The nodules were almost evenly disturbed in the right
(n = 1627, 50.2%) and the left (n = 1419, 43.8%) lobes, and
less frequently in the isthmus in 195 (6%). Those nodules
were located in the upper lobe in 355 (11%), middle lobe in
1481 (45.7%), lower lobe in 1210 (37.3%), and isthmus in
195 (6%). Nodule location was significantly different be-
tween benign and malignant nodules ( p < 0.0001). Malignant
nodules accounted for 14.6% (52/355), 10.2% (151/1481),
8.1% (98/1210), and 17.4% (34/195) of nodules in the upper
lobe, middle lobe, lower lobe, and isthmus, respectively. The
mean maximum size of thyroid nodules was 23.8 mm (–13.3)
with significant difference ( p < 0.0001) in size between be-
nign and malignant nodules (Table 2).
The distribution of ACR TI-RADS score (TR) among all
thyroid nodules was 8.9% TR1 (n = 288), 15.8% TR2
(n = 513), 22.9% TR3 (n = 742), 36.4% TR4 (n = 1179), and
16% TR5 (n = 519), with the majority of thyroid malignan-
cies classified as TR4 and 5 (Table 2).
A logistic regression model showed that location within
the thyroid is an independent risk factor in predicting thy-
roid cancer ( p = 0.005). Other known significant associations
with thyroid cancer included the following: composition
( p < 0.0001), echogenicity ( p < 0.0001), calcifications ( p <
0.0001), and margins ( p = 0.0001) (Supplementary Table S1).
This model was not included in the final regression model as
those features are included in the ACR TI-RADS points.
In the study presented here, nodules in the lower pole were
least likely to be malignant. Compared with the lower lobe
using a simple (univariate) logistic regression analysis, the
odds of a nodule being malignant were highest in nodules
located in the isthmus (OR = 2.4 [95% CI 1.6–3.6],
p < 0.0001), followed by upper lobe nodules (OR = 1.9 [CI
1.4–2.8], p = 0.0004) and then middle lobe nodules (OR = 1.3
[CI 0.9–1.7], p = 0.06) (Table 3).
This association held true after adjusting for each of the
following variables: age, sex, family history of thyroid can-
cer, radiation exposure, maximum nodule size, and ACR TI-
RADS score (Table 3). All of which, except radiation
Table 1. Patient Characteristics





Age in years, mean (range) 54.2 (18–97)
Race/Ethnicity




Native American 38 (1.2)
Pacific Islander 4 (0.12)
Other 63 (1.9)
Missing 95 (2.9)















Confluent (cannot determine) 19 (0.6)
Missing 66 (1.9)
FIG. 1. Thyroid nodule exclusion flowchart. B, benign;
M, malignant.















































exposure, were independently and significantly associated
with the risk of thyroid cancer in the univariate logistic re-
gression. Furthermore, all above variables, except maximum
nodule size, were independently and significantly associated
with the risk of thyroid cancer in the final multivariate logistic
regression model. In particular, the odds of a nodule being
malignant are higher in males than in females (OR = 1.8, [CI
1.4–2.5], p < 0.0001), lower as age progresses on a continuum
(OR = 0.9 [CI 0.97–0.99], p < 0.0001), higher in patients with
a positive family history of thyroid cancer (OR = 1.5 [CI 1.0–
2.2], p = 0.04), and higher with higher ACR TI-RADS levels
using TR1 as the reference TR2 (OR = 4.4 [CI 0.8–82.3],
p = 0.09), TR3 (OR = 13.1 [CI 2.8–233], p < 0.0001), TR4
(OR = 25.8 [CI 5.7–455], p < 0.0001), and TR5 (OR = 155.6
[CI 34.5–999.9], p < 0.0001). In looking into the points
contributing to the ACR TI-RADS, we confirmed that the risk
of thyroid cancer increased by 73% with each increase in the
score by one point (OR = 1.73 [CI 1.6–1.8], p < 0.0001).
Table 2. Thyroid Nodule Characteristics
Characteristic All data, n Benign Cancer p
Total, N (%) 3241 (100.0) 2906 (89.7) 335 (10.3) <0.0001*
Laterality (%)
Right 1627 (100.0) 1462 (89.9) 165 (10.1) 0.0031*
Left 1419 (100.0) 1283 (90.4) 136 (9.6)
Isthmus 195 (100.0) 161 (82.6) 34 (17.4)
Nodule location (%)
Upper 355 (100.0) 303 (85.4) 52 (14.6) <0.0001*
Middle 1481 (100.0) 1330 (89.8) 151 (10.2)
Lower 1210 (100.0) 1112 (91.9) 98 (8.1)
Isthmus 195 (100.0) 161 (82.6) 34 (17.4)
ACR TI-RADS score (%)
TR1 288 (100.0) 287 (99.7) 1 (0.3) <0.0001*
TR2 513 (100.0) 505 (98.4) 8 (1.6)
TR3 742 (100.0) 708 (95.4) 34 (4.6)
TR4 1179 (100.0) 1076 (91.3) 103 (8.7)
TR5 519 (100.0) 330 (63.6) 189 (36.4)
Maximum size, mean (SD), mm 23.8 (13.3) 24.2 (13.1) 20.3 (14.16) <0.0001
Upper 18.9 (9.2) 19.4 (9.3) 16.2 (7.9) 0.1058
Middle 25.4 (14.5) 25.8 (14.3) 22.2 (16.4) 0.0016
Lower 23.9 (12.6) 24.1 (12.5) 21.2 (13.4) 0.0362
Isthmus 20.3 (11.3) 21.3 (11.2) 15.6 (10.7) 0.0206
*p-Values refer to contingency analysis only of descriptive nature for the entire group (group characteristic vs. cancer diagnosis).
ACR, American College of Radiology; SD, standard deviation; TI-RADS, Thyroid Imaging Reporting and Data System.
Table 3. Thyroid Nodule Location and the Risk of Thyroid Malignancy Adjusted for Other Variables
Variables
Univariate analysis Multivariate analysis
Unadjusted model Adjusted model
OR (95% CI) p aOR (95% CI)a p
Nodule location
Isthmus 2.4 (1.6–3.6) <0.0001 2.4 (1.5–3.9) 0.0007
Upper 1.9 (1.4–2.8) 0.0004 1.8 (1.2–2.7) 0.0055
Middle 1.3 (0.9–1.7) 0.0607 1.5 (1.1–2.0) 0.0107
Lower—ref — — — —
Age 0.98 (0.97–0.99) <0.0001 0.98 (0.97–0.99) <0.0001
Sex (ref = female) 1.7 (1.3–2.2) <0.0001 1.8 (1.4–2.5) <0.0001
Family history (ref = no) 1.6 (1.2–2.2) 0.0055 1.5 (1.0–2.2) 0.0409
Radiation exposure (ref = no) 1.1 (0.8–1.4) 0.7496 — —
Maximum size 0.97 (0.96–0.98) <0.0001 0.97 (0.96–0.98) 0.6951
TIRADS
TR2 4.5 (0.8–84.6) 0.0871 4.4 (0.8–82.3) 0.0953
TR3 14.7 (3.2–261.5) <0.0001 13.1 (2.8–233.5) <0.0001
TR4 29.0 (6.4–510.9) <0.0001 25.8 (5.7–455.4) <0.0001
TR5 167.4 (37.3–999.9) <0.0001 155.6 (34.5–999.9) <0.0001
TR1–ref — — — —
aOR adjusted for age, sex, family history, radiation exposure, maximum size, and ACR-TIRADS.
CI, confidence interval; OR, odds ratio.















































Compared with lower lobe nodules, isthmus nodules
continued to demonstrate the highest risk of malignancy in a
multivariate regression model (OR = 2.4 [CI 1.5–3.9],
p = 0.0007), followed by upper lobe nodules (OR = 1.8 [CI
1.2–2.7], p = 0.005) and then middle lobe nodules (OR 1.5 [CI
1.1–2.0], p = 0.01) (Table 3). The higher risk of cancer in
nodules located in the upper lobe followed by the middle lobe
compared with the lower lobe remained significant when we
excluded the isthmus from this analysis.
Isthmus nodules were significantly smaller in size com-
pared with middle ( p < 0.0001) and lower ( p = 0.0004), but
not upper nodules ( p = 0.25). When adjusted for thyroid
cancer diagnosis, isthmus nodules remained significantly
smaller in size compared with middle ( p = 0.007) and lower
( p = 0.03), but not upper nodules ( p = 0.82), with a mean
size of 15.5 mm (–10.7) (Supplementary Tables S2 and S3).
Discussion
This study shows that thyroid nodule location is an inde-
pendent risk factor for thyroid cancer diagnosis even after
adjusting for other significant sonographic predictors of
thyroid cancer. While thyroid nodules located in the isthmus
were the least frequent (6%), they had the highest risk of
being malignant (OR = 2.4 [CI 1.4–3.8], p = 0.001). This risk
remained significant after adjusting for patient age, sex,
family history of thyroid cancer, radiation exposure, maxi-
mum nodule size, and ACR TI-RADS score. Furthermore,
malignant thyroid nodules located in the isthmus were sig-
nificantly smaller in size compared with other locations.
Thyroid nodules located in the lower lobe were associated
with the lowest risk of malignancy.
High-resolution neck US is widely used for evaluating
thyroid nodules, stratifying the risk of malignancy, and
guiding for FNA (6). Several sonographic features have been
described to predict the risk of thyroid cancer (primarily
papillary thyroid cancer) in a nodule, including solid com-
position, echogenicity (hypoechoic, in particular, markedly
hypoechoic), the presence of microcalcifications, and irreg-
ular margins, with improved specificity when a combination
of more than one feature is present (17–24).
Multiple professional societies use these US features to
predict the risk of cancer and together with nodule size pro-
vide management guidelines for FNA. The ATA and AACE
currently follow a pattern recognition approach to recom-
mend FNA of thyroid nodules based on size thresholds and
the level of clinical and sonographic suspicion (6,11). Using
similar sonographic features, but a point-based approach with
higher size thresholds, the ACR TI-RADS achieves a higher
accuracy and specificity and reduces the unnecessary FNA
rate. To maintain sensitivity, it substitutes US follow-up for
FNA in some nodules (15,25,26).
Our study confirms that thyroid nodule composition,
echogenicity, calcifications, and margins, but not vascu-
larity on color Doppler, are significant independent risk
factors for thyroid cancer in a multiple regression model.
This is not surprising given those features are well de-
scribed in the literature, and the fact that we performed a
secondary analysis of data used in evaluating the ACR TI-
RADS, which is based on those sonographic features (15).
When we added location of the nodule within the thyroid to
the above model, we found that it is an independent risk
factor to predict thyroid cancer adjusting for other known
sonographic features.
In many respects, our findings are in agreement with recent
reports proposing the use of thyroid nodule location in strat-
ifying the risk of thyroid cancer (13,14). Similar to our results,
both of these studies showed that the risk of malignancy was
lowest for lower lobe nodules and higher for upper and middle
lobe nodules. The ORs for upper and middle lobe nodules
were 4.7 and 9.7, respectively, in one study (11) and 5.8 and
3.7, respectively, in the other study (12). We also demonstrate
that the risk is higher in the upper pole, and to a lesser extent in
the middle lobe, but the ORs of 1.9 for the upper lobe and 1.3
for the middle lobe were much lower. The differences in the
OR are likely due to the very small sample sizes used to
analyze nodule location in the previous studies [189 total
nodules with 14 malignancies (11), and 225 total nodules with
12 malignancies (12)]. Single cases of malignant nodules in
the isthmus also precluded meaningful analysis of this loca-
tion in the prior studies. In our study, 34/195 nodules in the
isthmus were malignant, resulting in the highest OR of 2.4.
Proposed mechanisms for an increased risk in the upper
lobe include reactive oxygen species accumulation and in-
duction of cancer-promoting mutations due to the tortuous
route of the venous drainage of the upper lobes, as opposed to
the more direct venous drainage of the lower pole because the
inferior thyroid veins drain directly to the subclavian or
brachiocephalic veins, located just posterior to the manu-
brium (14). Dental and diagnostic irradiation may also play a
role in the increased risk of upper pole nodules (14).
It is not clear why thyroid nodules located in the isthmus
are more likely to be cancerous. The findings support the
concept that thyroid tissue should not be considered ho-
mogenous, and may determine not only the propensity to
form nodules but also risk of malignant transformation.
The majority of thyroid cancer usually arises in the thyroid
lobes with a small percentage arising from the thyroid isth-
mus. The reported rates of differentiated thyroid carcinoma
(DTC) located in the isthmus range from 1% to 9.2% for all
malignant thyroid nodules (27–33). In the present study, 1%
of malignant nodules were seen in the isthmus, which is
comparable with previous reports. The low incidence of DTC
in the isthmus likely reflects the small volume of the isthmus
relative to the lobes. Despite the low reported incidence, there
are some data suggesting that DTC originating from the thy-
roid isthmus tends to behave more aggressively and carries
poorer prognosis compared with that originating in thyroid
lobe (34). Papillary thyroid carcinoma in the isthmus tends to
be associated with more frequent lymph node metastases (35),
multifocality (27,28), capsular invasion, and extrathyroidal
extension (36), independent of tumor size (28). The aggres-
sive behavior of isthmic thyroid cancer is likely related to the
small size and thin shape of the isthmus, which may facilitate
the invasion of adjacent tissues. In addition, compared with
the lobes, the lymphatic drainage from the isthmus travels
more frequently to the prelaryngeal and pretracheal nodes and
then spreads to the paratracheal nodes (37–39).
The clinical risk factors for thyroid cancer such as age, sex
(male more than females), family history of thyroid cancer,
but not thyroid nodule size, are consistent with published data
(40). Radiation exposure, a known risk factor for thyroid
cancer (40), was not found to be a significant predictor of
thyroid cancer in our cohort. This is probably due to the fact















































that radiation exposure was self reported and not verified,
subjecting it to recall bias. It is also likely that thyroid cancers
that occur in the setting of prior radiation have similar so-
nographic features, and thus, similar ACR TI-RADS scores
as those that occur without prior radiation.
The strength of our study relies on the large sample size
that included comprehensive data points gathered from
multiple academic institutions with sonographic expertise,
allowing us to adjust for various confounding factors when
studying the risk of thyroid nodule location in predicting
thyroid cancer. The diagnosis of thyroid cancer was con-
firmed by cytology and/or surgical pathology. While the vast
majority of our study population had DTC, we included all
forms of thyroid malignancy in the data analysis. The limi-
tation of the study is the retrospective nature, which intro-
duces the risk of selection bias. We did not factor in the
margin of error that might be associated with cytology re-
sults, or adjust for solitary versus multiple thyroid nodules in
the analysis; the rationale is that thyroid nodules can carry a
similar risk of malignancy regardless of whether the patient
has a solitary nodule or multiple nodules (22).
In summary, thyroid nodule location appears to be an in-
dependent factor for the risk of thyroid cancer. Thyroid nod-
ules located in the isthmus have the highest risk of cancer
diagnosis, while nodules in the lower lobe have the lowest.
Furthermore, thyroid nodules located in the isthmus are sig-
nificantly smaller than nodules in the lobes mandating careful
evaluation of the isthmus on a routine thyroid sonogram. It is
also recommended that isthmus nodule location be factored in
when estimating the risk of thyroid cancer using current
guidelines, and future consideration be given to adding a point
to the ACR TI-RADS guidelines for nodule location in the
isthmus or using a lower size threshold for FNA or follow-up.
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